Individuals will have varying perspectives on whether surviving with severe disability is preferable to death." He emphasises the complexity of the predicament, stating, "This is an example of how science does not always provide us with simple answers. Professor Paul Young, Deputy Director and Intensive Care Medicine lead at the MRINZ, and PATCH-Trauma Study author, describes this research as a milestone in trauma care. However, this is the first study where the results indicate that TXA may be associated with a reduction in the survivor’s ability to lead an independent life. The PATCH-Trauma Study confirms the results of several prior studies - that TXA can stop bleeding and help save lives. Consequently, pre-hospital interventions for limiting bleeding are of paramount importance. Injury is the leading cause of death among young New Zealanders under 45, with most deaths occurring before reaching a hospital. The findings revealed that, on average, for every 100 patients who received TXA, there were four additional survivors at a six-month mark, but also four additional patients with severe disability requiring them to rely heavily on caregivers. In the study, patients were randomly assigned to receive pre-hospital TXA or a placebo, in addition to all usual care. Over the course of eight years, 1310 severely injured patients received treatment from 15 ambulance services and 21 trauma centres across New Zealand, Australia, and Germany. The PATCH-Trauma Study, coordinated in New Zealand by the Medical Research Institute of New Zealand (MRINZ), is a large trial in which treatment was administered at the scene of an accident or injury, or in an ambulance. The research examined TXA's effectiveness as a pre-emptive measure for patients at risk of life-threatening bleeding following trauma, an area of ongoing controversy. The Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Haemorrhage (PATCH-Trauma) Study focused on the use of tranexamic acid (TXA), a readily available drug known for its ability to limit bleeding during surgery. The PATCH-Trauma Study shines a new light on tranexamic acid’s role in pre-hospital treatment of major trauma.Ī ground-breaking study, published in the New England Journal of Medicine, conducted by researchers from Aotearoa New Zealand, Australia, and Germany, has raised a challenging question - In the event of severe injury, would individuals want to receive a treatment which reduced their probability of dying but also increased their risk of surviving severely disabled?
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |